A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancer

Phase 1

Recruiting

• Conditions: ung Cancer

• Registration Number: JPRN-UMIN000005143
• Lead Sponsor: Dokkyo Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-02-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1)Uncontrolled infection or Serious medical complications 2)Uncontrolled pleural effusion or ascites 3)Brain metastases 4)Serious disease condition 5)Uncontrolled diabetes mellitus 6)Therapeutic anticoagulopathy 7)Uncontrolled hyper tension 8)Current or previous history of GI perforation 9)interstitial lung disease or fibroid lung 10)history of drug-induced interstitial lung diseas 11)Current or previous history of hemoptysis 12)history of hemoptysis 13)Scheduling operation for examination time 14)Treatment history of carboplatin,pemetrexed,bevacizumab 15)Drug allergens 16)Multiple primary cancer 17)Serious psychiatric illness or psychological symptom 18)Women who are pregnant, lactating or with childbearing potential. 19)Ineligible based on decision of an investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
response rate

Secondary Outcome Measures

Name	Time	Method
Progression-free survival(PFS) Overall survival(OS) Safety